ethyl 9-(3,5-dichloro-4-pyridylcarbamoyl)-8-methoxy-1,2,3,4-tetrahydrobenzo[4,5]furo[3,2-c]pyridine-2-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: ethyl 9-(3,5-dichloro-4-pyridylcarbamoyl)-8-methoxy-1,2,3,4-tetrahydrobenzo[4,5]furo[3,2-c]pyridine-2-carboxylate
• 英文别名: ethyl 9-[(3,5-dichloropyridin-4-yl)carbamoyl]-8-methoxy-3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridine-2-carboxylate
• 化学式: C₂₁H₁₉Cl₂N₃O₅
• 分子量: 464.305
• InChiKey: VMZKEKCUORDEAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  93.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氨基-3,5-二氯吡啶 、 4-nitrophenyl (2-ethoxycarbonyl-6-methoxy-1,2,3,4-tetrahydro[1]benzofuro[3,2-c]pyridine)-9-carboxylate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 ethyl 9-(3,5-dichloro-4-pyridylcarbamoyl)-8-methoxy-1,2,3,4-tetrahydrobenzo[4,5]furo[3,2-c]pyridine-2-carboxylate
  参考文献：
  名称：

  NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

  摘要：

  本发明涉及新型磷酸二酯酶4型（PDE4）抑制剂的化学式（1）及其类似物、互变异构体、对映异构体、二对映异构体、位置异构体、立体异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化合物以及含有它们的制药组合物，这些制剂在治疗过敏性和炎症性疾病方面具有用途，包括哮喘、慢性支气管炎、特应性皮炎、荨麻疹、过敏性鼻炎、过敏性结膜炎、春季结膜炎、嗜酸性肉芽肿、牛皮癣、类风湿性关节炎、脓毒性休克、溃疡性结肠炎、克罗恩病、心肌再灌注损伤和脑再灌注损伤、慢性肾小球肾炎、内毒素休克和成人呼吸窘迫综合症。

  公开号：

  US20090306082A1

文献信息

• NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Gharat Laxmikant Atmaram

  公开号：US20110190303A1

  公开（公告）日：2011-08-04

  The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.

  本发明涉及一种新的磷酸二酯酶4型（PDE4）抑制剂，其化学式为（1）及其类似物、互变异构体、对映异构体、立体异构体、区域异构体、立体异构体、多晶型、药学上可接受的盐、适当的N-氧化物、药学上可接受的溶剂化物和含有它们的制药组合物，用于治疗过敏和炎症性疾病，包括哮喘、慢性支气管炎、特应性皮炎、荨麻疹、过敏性鼻炎、过敏性结膜炎、春季结膜炎、嗜酸性肉芽肿、牛皮癣、类风湿关节炎、脓毒症休克、溃疡性结肠炎、克隆病、心肌再灌注损伤和脑再灌注损伤、慢性肾小球肾炎、内毒素性休克和成人呼吸窘迫综合征。
• NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：EP1831227B1

  公开（公告）日：2013-06-19
• US7943634B2
  申请人：——

  公开号：US7943634B2

  公开（公告）日：2011-05-17
• US8129401B2
  申请人：——

  公开号：US8129401B2

  公开（公告）日：2012-03-06
• [EN] NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS<br/>[FR] NOUVEAUX COMPOSES HETEROCYCLIQUES UTILES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES ET ALLERGIQUES
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2006064355A2

  公开（公告）日：2006-06-22

  [EN] The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
  [FR] La présente invention concerne de nouveaux inhibiteurs de la phosphodiestérase de type 4 (PDE4) de formule (1) ainsi que des analogues, des tautomères, des énantiomères, des diastéromères, des régioisomères, des stéréoisomères, des polymorphes, des sels pharmaceutiquement acceptables, des N-oxydes appropriés et des solvates pharmaceutiquement acceptables de ces composés. L'invention concerne également des compositions pharmaceutiques les contenant, ces compositions étant utiles dans le traitement de maladies allergiques et inflammatoires telles que l'asthme, la bronchite chronique, la dermatite atopique, l'urticaire, la rhinite allergique, la conjonctivite allergique, la conjonctivite printanière, le granulome éosinophilique, le psoriasis, l'arthrite rhumatoïde, le choc septique, la rectocolite hémorragique, la maladie de Crohn, la lésion de reperfusion du myocarde et la lésion de reperfusion du cerveau, la glomérulonéphrite chronique, le choc endotoxique et le syndrome de détresse respiratoire de l'adulte.